Key Takeaways BDX enrolled the first patient in the XTRACT Registry to evaluate the Rotarex Catheter System for PAD.BDX's Rotarex system combines atherectomy and thrombectomy functions to treat PAD lesions effectively.BD aims to boost its PI business and improve patient outcomes through real-world evidence from the registry.Becton, Dickinson and Company (BDX) , popularly known as BD, announced the enrollment of the first patient in the XTRACT Registry. It is a prospective, multi-center, single-arm, post-mar ...

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the XTRACTâ"¢ Registry, a prospective, multi- center, single-arm, post-market registry study designed to evaluate the real-world performance of the Rotarexâ"¢ Catheter System in the treatment of patients with peripheral artery disease (PAD) lesions. BD Reaches Major Milestone for Rotarexâ"¢ Catheter System with First Patient Enrolled in XTRACTâ ...